Business
Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations
Press Release Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations Additional pre-planned analysis of the NCX 470 Denali trial completed NCX 470 maintains robust intraocular pressure lowering at 6, 9 and 12 monthsOther analyses broadly in line with the trends seen for Mont BlancData presentations planned for upcoming ophthalmology conferences October 2, 2025 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Gr
About this update from Nicox Sa
[{"type":"image","alt":"NICOX SA","displaySize":"","headline":null,"caption":"NICOX SA","className":"","disableSlideshowImg":false,"size":{"original":{"width":290,"height":177,"url":"https://media.zenfs.com/en/globenewswire.com/e5c6c949c0184e4a40b35f1bde81d2f8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rPuxYymeI_hpr5ShJmv9pw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI1NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e5c6c949c0184e4a40b35f1bde81d2f8","width":290,"height":177}},"lazy":false},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"3","style":"width:603px;border-bottom:solid black 1pt;vertical-align:top;","val":[{"type":"text","content":"Press Release ","length":13,"tagName":"p","attribs":{}}]}]},{"val":[{"colspan":"3","style":"width:603px;border-top:solid black 1pt;border-bottom:solid black 1pt;text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations","length":122,"tagName":"p","attribs":{}}]}]},{"val":[{"colspan":"3","style":"width:603px;vertical-align:top;","val":[{"type":"text","content":"","length":0,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Additional pre-planned analysis of the NCX 470 Denali trial completed","length":69,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":69,"olType":false},{"type":"text","content":"","length":0,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"NCX 470 maintains robust intraocular pressure lowering at 6, 9 and 12 months","length":76,"tagName":"p"}]},{"val":[{"type":"text","content":"Other analyses broadly in line with the trends seen for Mont Blanc","length":66,"tagName":"p"}]},{"val":[{"type":"text","content":"Data presentations planned for upcoming ophthalmology conferences","length":65,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":207,"olType":false},{"type":"text","content":"October 2, 2025 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that it has completed the additional pre-planned analyses of the NCX 470 Denali Phase 3 clinical trial data. These analyses confirm an efficacy profile similar to that seen ...